NICE Says No To Covering Bristol’s Orencia For Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will file an appeal to the decision within 10 working days, the firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis
U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.
Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis
U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.
NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA
Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.